Invention Grant
US09255146B2 Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
有权
针对Nogo-66受体（NgR）的中和单克隆抗体及其用途
- Patent Title: Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
- Patent Title (中): 针对Nogo-66受体（NgR）的中和单克隆抗体及其用途
-
Application No.: US14013916Application Date: 2013-08-29
-
Publication No.: US09255146B2Publication Date: 2016-02-09
- Inventor: Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
- Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
- Applicant Address: US IL North Chicago DE Weisbaden
- Assignee: ABBVIE INC.,ABBVIE DEUTSCHLAND GMBH & CO. KG
- Current Assignee: ABBVIE INC.,ABBVIE DEUTSCHLAND GMBH & CO. KG
- Current Assignee Address: US IL North Chicago DE Weisbaden
- Agency: Michael Best & Friedrich LLP
- Main IPC: C07H21/00
- IPC: C07H21/00 ; C12P21/06 ; C12N5/10 ; C12N15/63 ; C07K16/28 ; A61K39/00
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Public/Granted literature
- US20140065155A1 NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF Public/Granted day:2014-03-06
Information query
